Photodynamic therapy for chorioretinal diseases: a practical approach

Dijk, E.H.C. van; Rijssen, T.J. van; Subhi, Y.; Boon, C.J.F. (2020)

Article / Letter to editor

Photodynamic therapy (PDT) using verteporfin (Visudyne (R); Bausch + Lomb) is a treatment that is widely used to elicit cell and tissue death. In ophthalmology, PDT targets choroidal vascular abnormalities and induces selective occlusion of vessels. PDT was originally used in combination with full-dose verteporfin to treat neovascular age-related macular degeneration. Since the introduction of treatment with vascular endothelial growth factor receptor inhibitors, the clinical targets of PDT have shifted to other chorioretinal conditions, such as central serous chorioretinopathy, polypoidal choroidal vasculopathy, and choroidal hemangioma. In recent years, clinical studies have facilitated the optimization of treatment outcomes through changes in protocols, including the introduction of reduced treatment settings, such as PDT with half-dose verteporfin and half-fluence PDT. Here, we review PDT and its use for chorioretinal diseases from a practical perspective.

• Central serous chorioretinopathy
• Choroidal hemangioma
• Photodynamic therapy
• Polypoidal choroidal vasculopathy

• All authors: Dijk, E.H.C. van; Rijssen, T.J. van; Subhi, Y.; Boon, C.J.F.
• Date: 2020-04-11
• Journal: Ophthalmology and Therapy
• Volume: 9
• Issue: 2
• Pages: 329 - 342
• DOI: doi:10.1007/s40123-020-00250-0
• Link: https://link.springer.com/article/10.1007/s40123-020-00250-0